Stock Surge Buzz: Recent chatter on social media about Humacyte has been fueled by a notable 11% stock price increase in a single day. Many are discussing the high trading volume and the potential for continued momentum. There’s a sense of excitement as some point to bullish patterns and price targets.
Analyst Optimism: Discussions also highlight positive analyst sentiments, with several maintaining high price targets for the stock. Comments often focus on the company’s innovative biotech solutions, like infection-resistant vascular repair products. The tone suggests confidence in Humacyte’s long-term potential.
Note: This discussion summary was generated from an AI condensation of post data.
Humacyte Insider Trading Activity
Humacyte insiders have traded $HUMA stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $HUMA stock by insiders over the last 6 months:
- BRADY W DOUGAN has made 0 purchases and 3 sales selling 2,241,045 shares for an estimated $3,733,191.
- LAURA E NIKLASON (President, CEO and Director) has made 0 purchases and 3 sales selling 2,241,045 shares for an estimated $3,733,191.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Humacyte Hedge Fund Activity
We have seen 58 institutional investors add shares of Humacyte stock to their portfolio, and 77 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CENTERBOOK PARTNERS LP removed 3,146,628 shares (-91.7%) from their portfolio in Q3 2025, for an estimated $5,475,132
- STATE STREET CORP removed 1,983,068 shares (-45.2%) from their portfolio in Q3 2025, for an estimated $3,450,538
- MARSHALL WACE, LLP removed 1,820,240 shares (-69.0%) from their portfolio in Q3 2025, for an estimated $3,167,217
- MILLENNIUM MANAGEMENT LLC removed 1,406,109 shares (-55.1%) from their portfolio in Q3 2025, for an estimated $2,446,629
- MORGAN STANLEY added 720,158 shares (+52.3%) to their portfolio in Q3 2025, for an estimated $1,253,074
- NATIONAL BANK OF CANADA /FI/ removed 653,200 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,136,568
- GSA CAPITAL PARTNERS LLP removed 643,744 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,120,114
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Humacyte Analyst Ratings
Wall Street analysts have issued reports on $HUMA in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 11/21/2025
- D. Boral Capital issued a "Buy" rating on 11/20/2025
- Benchmark issued a "Buy" rating on 11/13/2025
- Barclays issued a "Overweight" rating on 08/27/2025
- HC Wainwright & Co. issued a "Buy" rating on 08/12/2025
To track analyst ratings and price targets for Humacyte, check out Quiver Quantitative's $HUMA forecast page.
Humacyte Price Targets
Multiple analysts have issued price targets for $HUMA recently. We have seen 6 analysts offer price targets for $HUMA in the last 6 months, with a median target of $4.75.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $25.0 on 01/08/2026
- Ryan Zimmerman from BTIG set a target price of $6.0 on 11/21/2025
- Bruce D. Jackson from Benchmark set a target price of $11.0 on 11/13/2025
- Matt Miksic from Barclays set a target price of $3.5 on 08/27/2025
- Joshua Jennings from TD Cowen set a target price of $3.5 on 08/12/2025
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $3.0 on 08/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
